New iPad Apps Unveiled To Aid Cancer Researchers And Their Patients
February 2, 2012
Two new cutting-edge iPad apps are set to be unveiled Friday morning at the 2012 Bone Marrow Transplant Tandem meetings in San Diego, California. Velos, Inc, a healthcare technology company, will introduce Velos Aversi and Velos Aversi GVHD, designed for use by medical professionals working in cancer trials and research, specifically bone marrow transplant or graft-versus-host disease.
Velos Aversi and Velos Aversi GVHD were created to provide a bedside tool to review previous records and evaluate patients in a visually friendly format. Clinicians will be able to quickly assess, track, and review patient data directly on an iPad, instead of relying on the current use of multiple, disjointed charts and time-consuming manual methods.
The unified data collection introduced with the Velos Adversi apps will potentially reduce the delay of important procedures, patient reviews, and decisions, which can negatively affect the patient and undermine the integrity of a clinical study.
"It's exciting to release our products to the Bone Marrow Transplant community at this meeting," said John McIlwain, CEO and President of Velos. "We think Velos Aversi GVHD's precise graft-versus-host Disease (GVHD) tracking make it an invaluable tool for bone marrow transplant procedures. Just as exciting is Velos Aversi's global applicability in all clinical trials in oncology," Mr. McIlwain added.
Velos has been dedicated to revolutionizing healthcare data collection since the company was founded in 1996. With the arrival of the Internet, and now the versatile iPad, Velos is focusing on creating tools to help expedite medical research and care.
Velos Aversi and Velos Aversi GVHD will be available for free.
Here at AppAdvice we are really excited by the promise of apps such as Velos Aversi and the potential they hold to aid in the advance of medical research. What do you think of the potential for the iPad in research? Feel free to discuss it in the comments.
